Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: Insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers

American Journal of Surgical Pathology

Volumn 36, Issue 4, 2012, Pages 601-611

  La Rosa, Stefano ^a   Marando, Alessandro ^b   Furlan, Daniela ^b   Sahnane, Nora ^b   Capella, Carlo ^b  

^a OSPEDALE DI CIRCOLO   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

adenoneuroendocrine carcinoma; colon; neuroendocrine carcinoma; prognosis; rectum

Indexed keywords

DNA; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CARCINOMA; COLORECTAL TUMOR; DNA METHYLATION; FEMALE; GENETIC EPIGENESIS; GENETICS; HUMAN; IMMUNOPHENOTYPING; MALE; METABOLISM; MICROSATELLITE INSTABILITY; MIDDLE AGED; MORTALITY; MULTIPLE CANCER; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; HUMANS; IMMUNOPHENOTYPING; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84859041362     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318242e21c     Document Type: Article

References (49)

1. Ahuja N, Mohan AL, Li Q, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res. 1997;57:3370-3374.
2. Akintola-Ogunremi O, Pfeifer JD, Tan BR, et al. Analysis of protein expression and gene mutation of c-kit in colorectal neuroendocrine carcinomas. Am J Surg Pathol. 2003;27:1551-1558.
3. Arnold CN, Nagasaka T, Goel A, et al. Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. Int J Cancer. 2008;123:1556-1564.
4. Arnold CN, Sosnowski A, Schmitt-Graff A, et al. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system. Int J Cancer. 2007;120: 2157-2164.
5. Barbareschi M, Roldo C, Zamboni G, et al. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Am J Surg Pathol. 2004;28: 1169-1176.
6. Chan AO, Broaddus RR, Houlihan PS, et al. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002;160:1823-1830.
7. Chan AO, Issa JP, Morris JS, et al. Concordant CpG island methylation in hyperplastic polyposis. Am J Pathol. 2002;160: 529-536.
8. Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001;125:228-231.
9. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol. 2003;16:376-388.
10. Dahlin AM, Henriksson ML, Van Guelpen B, et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor. Mod Pathol. 2011;24:671-682.
11. Erler BS, Presby MM, Finch M, et al. CD117, Ki-67, and p53 predict survival in neuroendocrine carcinomas, but not within the subgroup of small cell lung carcinoma. Tumor Biol. 2011;32:107-111.
12. Furlan D, Bernasconi B, Uccella S, et al. Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites. Clin Cancer Res. 2005;11: 1765-1775.
13. Furlan D, Cerutti R, Genasetti A, et al. Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut. Lab Invest. 2003;83:963-971.
14. Ghimenti C, Tannergard P, Wahlberg S, et al. Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. Br J Cancer. 1999;80:11-16.
15. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13: 535-540.
16. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122:1376-1387.
17. Hellebrekers DM, Lentjes MH, van den Bosch SM, et al. GATA4 and GATA5 are potential tumor suppressor and biomarkers in colorectal cancer. Clin Cancer Res. 2009;15:3990-3997.
18. Hiltunen MO, Koistinaho J, Alhonen L, et al. Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer. Br J Cancer. 1997;76:1124-1130.
19. House MG, Herman JG, Guo MZ, et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003;238:423-431.
20. Ishikubo T, Akagi K, Kurosumi M, et al. Immunohistochemical and mutational analysis of c-kit in gastrointestinal neuroendocrine cell carcinoma. Jpn J Clin Oncol. 2006;36:494-498.
21. Kato T, Terashima T, Tomida S, et al. Cytokeratin 20-positive large cell neuroendocrine carcinoma of the colon. Pathol Int. 2005;55:524-529.
22. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology. 2003;42: 137-140.
23. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29:181-206.
24. Kim YH, Lee HC, Kim SY, et al. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol. 2011;18:2338-2347.
25. Klöppel G, Rindi G, Anlauf M, et al. P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007;451(suppl 1):S9-S27.
26. La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors. Immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch. 2010;457:497-507.
27. La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol. 2011;42:1373-1384.
28. La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinico-pathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30-40.
29. La Rosa S, Rigoli E, Uccella S, et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch. 2004;445:248-254.
30. Li Y, Yau A, Schaeffer D, et al. Colorectal glandular-neuroendocrine mixed tumors: pathologic spectrum and clinical implications. Am J Surg Pathol. 2011;35:413-425.
31. Liu L, Broaddus RR, Yao JC, et al. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005;18:1632-1640.
32. Malpeli G, Amato E, Dandrea M, et al. Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. BMC Cancer. 2011;11:351.
33. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363:1283-1285.
34. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223.
35. Pages F, Galon J, Dieu-Nosjean MC, et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093-1102.
36. Power DG, Asmis TR, Tang LH, et al. High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. Med Oncol. 2010. [Epub ahead of print]. DOI: 10.1007/s12032-010-9674-1.
37. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, et al, ed. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press; 2010:13-14.
38. Rindi G, Bordi C, La Rosa S, et al. Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig Liver Dis. 2011;43(suppl 4):S356-S360.
39. Rindi G, Klöppel G, Couvelard A, et al. TNMstaging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762.
40. Schmitt AM, Riniker F, Anlauf M, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol. 2008;32:420-425.
41. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330-1338.
42. Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719-731.
43. Shida T, Furuya M, Nikaido T, et al. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. Clin Can Res. 2005;11:450-458.
44. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123: 1804-1811.
45. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17: 2257-2317.
46. Xu XL, Yu J, Zhang HY, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 2004;10:3441-3454.
47. Yang DT, Holden JA, Florell SR. CD117, CK20, TTF-1, and DNA topoisomerase II-a antigen expression in small cell tumors. J Cutan Pathol. 2004;31:254-261.
48. Zhang L, Smyrk TC, Oliveira AM, et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol. 2009;33:1562-1569.
49. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation toll in clinical medicine. Clin Chem. 1993;39:561-577.